World Mosquito Program Noumea - Human Sample Component

Arbovirus Infections Clinical Trial

Official title:

World Mosquito Program Noumea - Human Sample Component

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03552094
• Other study ID #: 2017-036
• Status: Recruiting
• Start date: June 25, 2018
• Est. completion date: June 2023

Study information

• Verified date: February 2022
• Source: Institut Pasteur
• Contact: Vincent Richard
• Phone: +687 27.26.66
• Email: vrichard[@]pasteur.nc
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacteria Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging. The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea.

Description:

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, disease vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and disease vector control must today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacterium Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging. The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the bacterium Wolbachia for the planned insect release program in Noumea. The establishment of Wolbachia in Aedes aegypti populations in Noumea should lead to the reduction of active transmission of dengue, Zika and chikungunya in the municipality.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: June 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All adult hemochromatosis or polycythemia patients or healthy donors have given their written consent to participate in the study and for the collection of a blood sample.

Exclusion Criteria:

• Participation refusal
• Minor person
• Positive result by Reverse transcription polymerase chain reaction RT-PCR for arboviruses
• Invalid qualification of the blood donation

Related Conditions & MeSH terms

• Arbovirus Infections

Intervention

Other:
• Blood donations of hemochromatosis or polycythemia patients
Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
• Blood donations of healthy donors
Blood samples are from blood donations of healthy donors.

Locations

Country	Name	City	State
France	Centre Hospitalier de Nouvelle-Calédonie	Nouméa	Nouvelle-Calédonie

Sponsors (2)

Lead Sponsor	Collaborator
Institut Pasteur	Institut Pasteur of New Caledonia

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Generation of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria	Generation of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea by measuring the Aedes aegypti female gorging rate	36 months
Primary	Maintenance and amplification of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria	Maintenance and amplification of Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea by measuring the number of eggs per Aedes Aegypti female gorged	36 months
Secondary	Vector competence assessment of the different Aedes aegypti Caledonian lineages	Assessment of the vector competence for the dengue, Zika and chikungunya viruses of the different Aedes aegypti Caledonian lineages with or without Wolbachia bacteria carriage by measuring the transmissibility reduction of Aedes aegypti carrying Wolbachia for arboviruses	36 months